OneMedNet Corp (ONMD) · Nov 6, 2026 · Earnings
Guidance issued — Q4 revenue forecast of approximately $12M-$14M
OneMedNet’s earnings update shows Q3 revenue acceleration and a dramatic Q4 forecast, but the outlook depends on customers accepting delivered data.
OneMedNet is transitioning from its decommissioned BEAM platform toward an iRWD business that sells curated, de-identified medical and clinical data to drugmakers, device companies, and AI developers. That pivot was beginning to show in 2025, when data-delivery revenue reached $1.254 million, while the company’s first-half 2026 revenue was still only $388,000.
| Q3 2026 | Q2 2026 | Q3 2025 | |
|---|---|---|---|
| Revenue (Press release) | $1.0M | $0.292M | ~$0.177M |
| Q4 revenue guidance (Press release) | $12M-$14M |
The quarter shows real commercial conversion, not just a larger sales funnel. OneMedNet expects roughly $1 million of Q3 revenue, up 242% from the prior quarter and 465% from the year-earlier quarter. That is meaningful because the company had previously been describing customer pipeline and bookings momentum; this update says deliveries have started converting into recognized revenue at scale.
The Q4 outlook is the material change, but it is still execution-dependent. The company forecasts $12 million to $14 million of Q4 revenue—roughly 12 to 14 times the preliminary Q3 figure—pending customer acceptance of delivered data. There is no reliable published consensus to establish a formal beat, so the better benchmark is the standing story: the direction of acceleration was already telegraphed, but this magnitude would represent a sharp step-up if the data is accepted and revenue is recognized.
The evidence is encouraging, but the forecast is not yet fully validated. Q3 revenue remains preliminary and may change when the company files its 10-Q, while the Q4 range depends on customer acceptance rather than signed delivery alone. 〔0〕 The filing therefore advances the commercialization story, but it does not yet prove that the projected Q4 run rate is repeatable.
Bottom line: This is a meaningful early validation of OneMedNet’s shift from building its data platform to monetizing it. The Q4 forecast is potentially transformative relative to the company’s small historical revenue base, but customer acceptance and the upcoming 10-Q are the key confirmation points.
Q3 10-Q expected by November 16, 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!